Compounds > pargyline
Page last updated: 2024-11-02

pargyline and Essential Hypertension

pargyline has been researched along with Essential Hypertension in 2 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Essential Hypertension: Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
MIZGALA, HF1
BARRERAARENAS, F1

Reviews

1 review available for pargyline and Essential Hypertension

ArticleYear
NEWER DRUGS IN THE TREATMENT OF HYPERTENSION.
    Canadian Medical Association journal, 1965, Apr-24, Volume: 92

    Topics: Antihypertensive Agents; Bretylium Compounds; Chlorothiazide; Chlorthalidone; Diuretics; Drug Therap

1965

Other Studies

1 other study available for pargyline and Essential Hypertension

ArticleYear
[CLINICAL TRIAL WITH THE COMBINATION OF PARGYLINE AND METHYCLOTHIAZIDE IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION].
    Medicina, 1965, Mar-10, Volume: 45

    Topics: Drug Therapy; Essential Hypertension; Humans; Hypertension; Methyclothiazide; Pargyline

1965